Literature DB >> 20349079

Guillain-Barré syndrome after short-course efalizumab treatment.

Marco Turatti, Stefano Tamburin, Domenico Idone, Maria Luigia Praitano, Giampietro Zanette.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20349079     DOI： 10.1007/s00415-010-5521-8

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  6 in total

Review 1.  Approaches for identifying and defining environmentally associated rheumatic disorders.

Authors:  F W Miller; E V Hess; D J Clauw; P A Hertzman; T Pincus; R M Silver; M D Mayes; J Varga; T A Medsger; L A Love
Journal:  Arthritis Rheum       Date:  2000-02

2.  A case of natural killer cell monoclonal expansion during efalizumab treatment in a patient with psoriasis.

Authors:  M Caproni; W Volpi; C Chiarini; E Antiga; B Giomi; P Fabbri
Journal:  Br J Dermatol       Date:  2009-02-23       Impact factor: 9.302

3.  Efalizumab-associated Guillain-Barre syndrome.

Authors:  Frank Victor; Kavita Menon; Jo-Ann M Latkowski; Adolfo Fernandez-Obregon; Bruce E Strober
Journal:  Arch Dermatol       Date:  2008-10

4.  Non-T(H)1 cytokines are augmented systematically early in Guillain-Barré syndrome.

Authors:  Rayomand Press; V Ozenci; M Kouwenhoven; H Link
Journal:  Neurology       Date:  2002-02-12       Impact factor: 9.910

Review 5.  Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome.

Authors:  Pieter A van Doorn; Liselotte Ruts; Bart C Jacobs
Journal:  Lancet Neurol       Date:  2008-10       Impact factor: 44.182

Review 6.  Tumor necrosis factor-alpha antagonists and neuropathy.

Authors:  Joerg-Patrick Stübgen
Journal:  Muscle Nerve       Date:  2008-03       Impact factor: 3.217
  6 in total
  2 in total

Review 1.  Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome.

Authors:  Jane Pritchard; Richard Ac Hughes; Robert Dm Hadden; Ruth Brassington
Journal:  Cochrane Database Syst Rev       Date:  2016-11-15

2.  Severe meningo-radiculo-neuritis associated with ipilimumab.

Authors:  Flavie Bompaire; Christine Mateus; Hervé Taillia; Thierry De Greslan; Marion Lahutte; Magali Sallansonnet-Froment; Madani Ouologuem; Jean-Luc Renard; Guy Gorochov; Caroline Robert; Damien Ricard
Journal:  Invest New Drugs       Date:  2012-01-11       Impact factor: 3.651
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.